U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701161) titled 'Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device' on July 08.
Brief Summary: This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Study Start Date: Jan. 13, 2025
Study Type: OBSERVATIONAL
Condition:
Alzheimer s Disease
MCI Conversion to Dementia
pTau217
Biomarkers
Recruitment Status: RECRUITING
Sponsor: Neurogen Biomarking LLC
Published by HT Digital Content Services with permission from Health Daily Digest...